ロサルタン。ニューロタン
WordNet
- the 14th letter of the Roman alphabet (同)n
- the 13th letter of the Greek alphabet
- (Old Testament) nephew of Abraham; God destroyed Sodom and Gomorrah but chose to spare Lot and his family who were told to flee without looking back at the destruction
- burbot (同)genus Lota
PrepTutorEJDIC
- nitrogenの化学記号
- ニュー(ギリシア語アルファベットの第13字Ν,ν;英語のN,nに相当)
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 1型糖尿病の予防 prevention of type 1 diabetes mellitus
- 2. 手術室で使用される局所止血剤および組織接着剤の概要 overview of topical hemostatic agents and tissues adhesives used in the operating room
English Journal
- Clinical outcome of patients with chronic heart failure followed in a specialized heart failure center.
- Gotsman I1, Zwas D, Zemora Z, Jabara R, Admon D, Lotan C, Keren A.
- The Israel Medical Association journal : IMAJ.Isr Med Assoc J.2011 Aug;13(8):468-73.
- BACKGROUND: Patients with heart failure (HF) have a poor prognosis. Heart failure centers with specialized nurse-supervised management programs have been proposed to improve prognosis.OBJECTIVES: To evaluate the clinical outcome of patients with HF treated at a multidisciplinary HF center of Clalit
- PMID 21910370
- National survey 2007 on medical services for persons with intellectual disability in residential care in Israel.
- Merrick J1, Kandel I, Lotan M, Aspler S, Fuchs BS, Morad M.
- International journal of adolescent medicine and health.Int J Adolesc Med Health.2010 Oct-Dec;22(4):575-82.
- In Israel, the Office of the Medical Director of the Ministry of Social Affairs is responsible for the medical service in residential-care centers for persons with intellectual disability (ID). A standard annual questionnaire was developed during 1997-1998, and the first national survey study was co
- PMID 21404888
- Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.
- Remzi M1, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF.
- BJU international.BJU Int.2009 Feb;103(3):307-11. doi: 10.1111/j.1464-410X.2008.08003.x. Epub 2008 Oct 16.
- OBJECTIVE: To assess whether tumour architecture can help to refine the prognosis of patients treated with nephroureterectomy (NU) for urothelial carcinoma (UC) of the upper urinary tract (UT), as the prognostic value of tumour architecture (papillary vs sessile) in UTUC remains elusive.PATIENTS AND
- PMID 18990163
Japanese Journal
- OJ-256 Electrophysiological Improvement of The Atrium by Losartan Potassium (Nu-Lotan^[○!R]) in Hypertensive Patients(ECG/Body Surface Potential Mapping/Holter 3 (A) : OJ30)(Oral Presentation (Japanese))
- Kawano Tomohito,Nomura Masahiro,Miyazaki Shinichirou,Uemura Eiko,Kageyama Norihito,Kimura Eriko,Yamaguchi Koji,Kusunoki Kanji,Tanaka Eiji,Wakatsuki Tetsuzo,Tabata Tomotsugu,Nishikado Akiyoshi,Saitoh Ken,Nakaya Yutaka,Itoh Susumu
- Circulation journal : official journal of the Japanese Circulation Society 68(Supplement_I), 291, 2004-03-01
- NAID 110002700856
- A-IIアンタゴニスト : 医薬品名 : ロサルタンカリウム losartan potassium ; 商品名(販売会社名) : ニューロタン錠25, 50 Nu-lotan(萬有) ; 二重盲検試験の対照薬 : マレイン酸エナラプリム ; 特許情報 : 特許番号第1819199号 ; 日本標準商品分類番号 : 872149 ; 承認年月日 : 平成10年7月3日
Related Links
- (Nu-Lotan) チェック 「副作用」副作用の種類」「薬効分類」 「高血圧症」「糖尿病性腎症」 ニューロタン 副作用(五十音順) 意識喪失 ・胃潰瘍 ・胃部の不快感 ・LDH上昇 ・かすみ目 ・かゆみ ・肝機能障害 ・起立性低血圧 急性 ...
- MSDが提供する医療関係者向けサイトです。アンジオテンシンⅡ受容体拮抗薬 ニューロタン®のページです。 ... 高血圧症における国内で実施された臨床試験(治験時)で副作用が報告されたのは709例中71例(10.0%)であり、主な副作用 ...
Related Pictures
★リンクテーブル★
[★]
- 英
- losartan
- 化
- ロサルタンカリウム losartan potassium
- 商
- ニューロタン Nu-Lotan、プレミネント配合
[★]